<DOC>
	<DOCNO>NCT00430157</DOCNO>
	<brief_summary>This study patient seasonal allergic rhinitis ( SAR ) compare effect versus placebo repeat dose intranasal GSK256066 use Vienna Challenge Chamber . GSK256066 potent highly selective phosphodiesterase-4 ( PDE4 ) inhibitor , currently development GSK treatment allergic rhinitis , asthma COPD . Subjects select basis display define moderate response pre-determined dose use . This study aim explore action repeat dos intranasal GSK256066 patient Seasonal Allergic Rhinitis Vienna Challenge Chamber compare placebo . 12-lead ECG , vital sign adverse event enquiry make throughout study . Nasal examination , symptom score ( TNSS ) , nasal lavage , nasal scrape allergen challenge assessment also perform various time point throughout study .</brief_summary>
	<brief_title>Trial With Allergic Rhinitis Patients Taking GSK256066 Versus Placebo In A Pollen Challenge Chamber</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>6- ( ( 3- ( ( dimethylamino ) carbonyl ) phenyl ) sulfonyl ) -8-methyl-4- ( ( 3-methyloxyphenyl ) amino ) -3-quinolinecarboxamide</mesh_term>
	<criteria>The subject healthy . They age 18 50 year inclusive . Body mass index less 29.0 kg/mÂ² weight range 55.0kg ( female 50kg ) 95.0kg inclusive . They history seasonal allergic rhinitis They exhibit moderate response 1500 grass pollen grains/m3 2h Vienna Challenge Chamber , They positive skin prick test grass pollen within 12 month precede screen visit . They positive RAST grass pollen within 12 month precede screen visit . They current nonsmoker use tobacco product 6 month precede screen visit They must baseline FEV1 &gt; 80 % predict baseline FEV1 ( maximum record value ) / FVC ( associate value ) &gt; 70 % predict . Pregnant nursing female . Women childbearing potential unwilling unable use appropriate method contraception . structural nasal abnormality nasal polyposis , history frequent nosebleed , recent nasal surgery recent ( within 2 week ) ongoing upper respiratory tract infection . The subject likely unable abstain salbutamol use 8 hour challenge The subject history drug allergy The subject concurrently participate another clinical study past 3 month A supine blood pressure persistently high 140/90 millimetre mercury ( mmHg ) screen A supine mean heart rate outside range 4090 beat per minute ( bpm ) screening . The subject donate unit blood within previous 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Vienna Challenge Chamber</keyword>
	<keyword>Seasonal Allergic Rhinitis</keyword>
	<keyword>Inflammation</keyword>
</DOC>